DONGGUAN, China, Dec. 8, 2025 /PRNewswire/ — PT Fapon Bioindustries Indonesia (referred to as “PT Fapon”) and the Indonesian state-owned pharmaceutical holding company PT Bio Farma (Persero) (referred to as “Bio Farma”) officially signed a cooperation agreement at Fapon’s headquarters in Dongguan. The partnership is centered on the local manufacturing, and commercialization of IVD products in Indonesia.

Mrs. Dyah, Chief Executive Officer of Fapon Indonesia Market, and Mr. Dicky, Head of the Business Development Division at Bio Farma, formally executed the agreement on behalf of their respective organizations. This collaboration represents a major advancement in localizing diagnostic technologies and upgrading Indonesia’s healthcare industry.

“We are excited to strengthen our partnership with PT Fapon to localize the production of high-end IVD products in Indonesia,” said Mr. Shadiq Akasya, President Director of Bio Farma. “This collaboration will bolster our national capabilities in medical device manufacturing, thereby enabling broader disease detection coverage across Indonesia.”

Mr. Ben He, President of Fapon Biotech, stated, “PT Fapon is deeply committed to fostering the growth of Indonesia’s healthcare industry through meaningful technology partnerships. We are confident that this technology transfer and localization project will provide Indonesia with cutting-edge diagnostic solutions, and help build a more resilient and sustainable healthcare future.”

PT Fapon is Fapon Group’s first overseas manufacturing base, dedicated to supplying the Indonesian and regional markets with diagnostic products and solutions that meet international standards. Bio Farma, with a legacy spanning over 130 years, is a leading national life science enterprise in Indonesia, boasting extensive expertise in the research, development, production, and distribution of vaccines, biologics, and pharmaceutical products.

This partnership marks a significant milestone in PT Fapon’s strategy to deepen its local roots and empower the autonomous development of Indonesia’s medical industry. Looking ahead, both parties plan to explore further collaborative opportunities in medical innovation and technology transferring, jointly driving progress in healthcare across Indonesia and Southeast Asia.

About PT Fapon Bioindustries Indonesia

PT Fapon Bioindustries Indonesia, located in West Java, is Fapon’s first international manufacturing base. The facility is built and operated in strict compliance with ISO 14644 standards and is dedicated to delivering high-quality in-vitro diagnostic (IVD) products and solutions to the Indonesian market. Leveraging the Fapon Group’s global R&D, manufacturing, and service network, PT Fapon actively introduces advanced diagnostic technologies to support the growth of Indonesia’s local healthcare industry, improve diagnostic accessibility, and contribute to enhancing public health in the country.

About PT Bio Farma (Persero)

PT Bio Farma (Persero) is a world-class, globally competitive life science company that has a role to provide and develop international standard life science products to improve the quality of life. Supported by competence, experience and learning process for more than 130 years, Bio Farma is present as part of the struggle to save and improve the quality of human life. Given the important role in building the nation’s health, Bio Farma’s existence is maintained from time to time.

• Voranigo® has been awarded the Prix Galien USA, the Prix Galien Poland and the Prix Galien Bridges Awards for Best Product for Orphan/Rare Diseases.
• These awards across several geographies recognize the progress represented by Voranigo® for patients living with glioma.

SURESNES, France, Dec. 8, 2025 /PRNewswire/ — Servier, an independent international pharmaceutical group governed by a foundation, today announced that Voranigo^® (vorasidenib) has been awarded the inaugural 2025 Prix Galien Bridges Award for Best Product for Orphan/Rare Diseases, during a ceremony held in Stockholm. The Prix Galien Bridges Award recognize outstanding life science innovation across the Nordic countries and their growing bridges with biopharmaceutical communities in key European and Middle Eastern countries, including Austria, Israel, The Netherlands, Portugal, and Spain.

Servier recently announced that Voranigo^® also won the Prix Galien USA Award in the Best Product for Orphan/Rare Diseases category, as well as the Prix Galien Poland Award.

The Prix Galien Award recognizes breakthrough products and outstanding research teams across the pharmaceutical, biotech, medtech, and digital health fields.

“We are truly honored to receive these prestigious distinctions in several countries. It recognizes the scientific progress that Voranigo^® can bring to patients living with glioma across the world”, said Arnaud Lallouette, Executive Vice-President, Global Medical & Patient Affairs. “It rewards Servier’s commitment to innovation and to patients as we continue to advance precision oncology for all who stand to benefit.”

Voranigo^® has been granted marketing authorization for the treatment of predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an isocitrate dehydrogenase-1 (IDH1) R132 or isocitrate dehydrogenase-2 (IDH2) R172 mutation in adult and adolescent patients aged 12 years and older and weighing at least 40 kg who only had surgical intervention and who are not in immediate need of radiotherapy or chemotherapy. in the United States, Canada, Australia, Israel, the United Arab Emirates, Saudi Arabia, Switzerland, Brazil, the United Kingdom, in Japan and Europe (27 countries of the European Union as well as Iceland, Liechtenstein and Norway).

Press Contact
presse@servier.com 

About Servier 
Servier is an independent international pharmaceutical company. To find out more please visit the Group website: servier.com
Follow us on social media: LinkedIn, Facebook, X, Instagram 

References  

1. Mellinghoff, I. K., van den Bent, M. J., Blumenthal, D. T., Touat, M., Peters, K. B., Clarke, J., Mendez, J., Yust-Katz, S., Welsh, L., Mason, W. P., Ducray, F., Umemura, Y., Nabors, B., Holdhoff, M., Hottinger, A. F., Arakawa, Y., Sepulveda, J. M., Wick, W., Soffietti, R., … Cloughesy, T. F. (2023). Vorasidenib in idh1- or IDH2-mutant low-grade glioma. New England Journal of Medicine, 389(7), 589–601. https://doi.org/10.1056/nejmoa2304194 
2. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106. PMID: 34185076; PMCID: PMC8328013. 

SINGAPORE, Dec. 8, 2025 /PRNewswire/ — In 2025, Mantle entered a new phase of its evolution. What began as a high-performance Layer-2 rapidly transformed into a full-stack on-chain financial ecosystem, uniting infrastructure, liquidity, institutions, builders, creators, and global communities.

The release of Mantle “2025 RWApped” captures this shift — a year defined by accelerating institutional momentum, rapid RWA expansion, and Mantle’s growing role as the distribution layer connecting traditional finance with on-chain liquidity.

Ecosystem MoMNTum at Scale

In 2025, Mantle reached multiple ecosystem all-time highs, signaling its progression into a more mature, institution-ready network:

• Top-30 ranking on CoinMarketCap & CoinGecko at ATH
• Treasury peaked above $7.9B
• TVL surpassed $2.2B
• Stablecoin supply exceeded $750M
• Global community topped 1M members
• 200+ ecosystem partners and dApps across DeFi, RWAs, infrastructure, and consumer applications

These milestones marked Mantle’s emergence as a credible on-chain venue for real-world finance.

Infrastructure Built for the RWA Era

Two major upgrades in 2025 established Mantle as a high-throughput, institutional-grade settlement layer:

• EigenLayer Integration: As the first and largest L2 to partner with EigenLayer, Mantle unlocked modular security, shared validation, enhanced censorship resistance, and enterprise-grade scalability.
• OP-Succinct via Succinct Labs: Mantle became the first OP Stack L2 to launch as a ZK Validity Rollup, and the largest ZK rollup by TVL, enabling faster settlement, safer execution, and frictionless capital flow between real-world and digital markets.

Together, these upgrades positioned Mantle as an execution and settlement layer for compliant, high-volume RWA activity.

Deep CeFi Integration with Bybit

A core driver of Mantle’s 2025 expansion was its deep, native integration across the Bybit ecosystem, embedding $MNT across spot markets, institutional trading desks, and VIP liquidity programs. This transformed $MNT into a true CeFi-native asset, driving large-scale participation from both retail and institutional traders and forming a powerful distribution bridge between centralized exchange liquidity and on-chain finance.

Global Liquidity Across CeFi and DeFi

As adoption scaled, Mantle’s liquidity footprint expanded worldwide across platforms including Coinbase, Hyperliquid, Moomoo, Backpack, and Coinhako, ensuring seamless access for retail users, professional traders, and institutions deploying capital into Mantle-native applications.

Builders, Creators & Global Community

Ecosystem growth in 2025 was powered by people. Mantle hosted its largest global hackathon to date with 800+ builders, and launched the industry’s first RWA Scholars Program, selecting 6 scholars from 5 countries from over 2,000 global creator submissions.

Mantle also activated its community worldwide through:

• 67 global AMAs
• 25 international events
• 12 developer meetups
• 19 online activations

From ETHDenver and TOKEN2049 to Korea Blockchain Week and CCCC Lisbon, Mantle’s presence became truly global.

Key Strategic Milestones

• 5 Aug 2025 — The Bybit Era Begins: Mantle became the heart of Bybit’s on-chain ecosystem; Helen Liu and Emily Bao joined as Key Advisors.
• 1 Oct 2025 — The RWA Pivot: Mantle went all-in on RWAs with major integrations including Anchorage, Backed/xStocks, Aave, DMZ Finance, Ethena, Agora, and Securitize.
• Oct 2025 — Builders Activated: Launch of Mantle’s First Global Hackathon.
• Nov 2025 — Education Meets RWAs: Debut of the RWA Scholars Program at CCCC Lisbon.

By year-end, Mantle had transitioned from RWA strategy to full ecosystem execution, firmly positioning itself as a distribution layer connecting traditional finance with on-chain liquidity.

Looking Ahead to 2026

With infrastructure hardened, liquidity globalized, and institutional momentum accelerating, Mantle enters 2026 focused on:

• Scaling real-world assets on-chain
• Deepening institutional finance integration
• Expanding global distribution and developer adoption

The MoMNTum continues.

About Mantle

Mantle positions itself as the premier distribution layer and gateway for institutions and TradFi to connect with onchain liquidity and access real-world assets, powering how real-world finance flows.

With over $4B+ in community-owned assets, Mantle combines credibility, liquidity and scalability with institutional-grade infrastructure to support large-scale adoption. The ecosystem is anchored by $MNT within Bybit, and built out through core ecosystem projects like mETH, fBTC, MI4 and more. This is complemented by Mantle Network’s partnerships with leading issuers and protocols such as Ethena USDe, Ondo USDY, OP-Succinct and EigenLayer.

For more information about Mantle, please visit: mantle.xyz
For more social updates, please follow: Mantle Official X & Mantle Community Channel
For media enquiries, please contact: contact@mantle.xyz

PANAMA CITY, Dec. 8, 2025 /PRNewswire/ — BingX, a leading cryptocurrency exchange and Web3 AI company, today announced a major upgrade to its copy trading, celebrating a milestone of 1.3 billion cumulative copy trading orders. The update introduces a revamped interface, optimized workflows, and advanced customization features that empower traders by making trading simpler and more user-centric.

The new version enhances every layer of the copy trading experience:

• New and Improved Interface: The revamped copy trading interface delivers easy viewing and access to key information and streamlined settings.
• Faster Copy Trading Management: Creating and managing copy trades is now faster and more intuitive, with a simplified set of steps and configuration options.
• Refined Copying Modes: Users can now simply choose between Fixed Ratio Copying and Fixed Amount Copying, with reworked, simplified settings for precise trade mirroring.
• Customizable Leverage and Trading Pairs: Users can now independently set leverage levels and select trading pairs, enabling greater flexibility to match individual risk preferences and strategies.
• Real-Time Fund Synchronization: Account balances across funding, spot, and futures wallets update instantly, ensuring seamless trade execution and accurate capital allocation.

The upgrade also introduces 0-slippage execution for accurate price replication, copy-trade insurance to offset potential losses, and AI trader analytics that evaluate performance data to help users identify high-quality lead traders. With automated take-profit functions and dynamic stop-loss options, users can now manage trades more efficiently and with greater confidence.

“The upgrade represents our ongoing commitment to refining every detail of the user experience,” said Vivien Lin, Chief Product Officer at BingX. “Copy trading is one area where BingX has truly made its mark in the crypto industry. This update reflects years of feedback and innovation — making the process more transparent, flexible, and accessible for both new and experienced users.”

About BingX 

Founded in 2018, BingX is a leading crypto exchange and Web3 AI company, serving a global community of over 20 million users. With a comprehensive suite of AI-powered products and services, including derivatives, spot trading, and copy trading, BingX caters to the evolving needs of users across all experience levels, from beginners to professionals. Committed to building a trustworthy and intelligent trading platform, BingX empowers users with innovative tools designed to enhance performance and confidence. In 2024, BingX proudly became the official crypto exchange partner of Chelsea Football Club, marking an exciting debut in the world of sports sponsorship.

For more information, please visit: https://bingx.com/

Latest release enables faster, more confident design decisions at scale with accelerated simulation, AI-powered, real-time feedback, and GPU-accelerated reduced order modeling

TROY, Mich., Dec. 8, 2025 /PRNewswire/ — Altair, a global leader in computational intelligence and now part of leading technology company, Siemens, announced the latest updates to HyperWorks^® 2026 software. With significant advances in AI, high-performance computing (HPC), and multiphysics integration, HyperWorks 2026 enables engineering teams to accelerate innovation and improve product performance across industries using comprehensive computer-aided engineering (CAE) design and simulation.

Altair announced the latest updates to HyperWorks® 2026 software, including significant advances in AI, HPC, and multiphysics integration.

“HyperWorks 2026 exemplifies how Altair and Siemens are driving the future of simulation and empowering engineers to design smarter, faster, and with greater confidence in real-world outcomes by bringing AI, automation, and multiphysics into a unified ecosystem,” said Sam Mahalingam, chief technology officer, Altair, and executive vice president, Siemens Digital Industries Software. “Following the acquisition by Siemens earlier this year, our commitment is to create the world’s most complete AI-powered portfolio of product lifecycle intelligence software and further enhance the most comprehensive digital twin.”

HyperWorks in use at JetZero
JetZero, a pioneering aviation startup building the future of ultra-efficient air travel, is collaborating with Siemens on the development and production of JetZero’s revolutionary blended wing aircraft. The innovative all-wing design aims to improve fuel efficiency by up to 50 percent, reduce noise, and advance the industry toward zero carbon emissions. Key to the fast pace of its development schedule is gaining engineering insights faster than using conventional high fidelity computational fluid dynamics (CFD) with FlightStream, part of the HyperWorks suite.

As John Vassberg, chief design officer at JetZero explains, “JetZero is pioneering the next step change in the aerospace industry and, to accomplish that at the scale the industry is demanding, means we need a toolset that allows us to work at pace and gain accurate insights early in design – which FlightStream does. It is easy for our engineering team to use, does not require the traditional high-performance computing resources of high-fidelity CFD, and gets us answers fast and without heavy resource demands. This is critical for companies like JetZero that need to iterate faster than ever before.”

HyperWorks 2026 delivers six key innovations

AI-powered design and simulation
Geometric deep learning and generative algorithms and GPU-accelerated reduced order modeling (ROM) enable near-real-time predictions and faster validation. Physics-based AI models can be deployed in secure, browser-based environments, producing results up to 1,000x faster than traditional solver simulations. Expanded support for vectors and smoothed-particle hydrodynamics (SPH) broadens domain coverage.

Enterprise-scale pre-processing and model assembly
Engineers can now simulate large, complex assemblies with speed and fluidity, shortening build and validation cycles. Enhanced navigation, batch meshing, and connector management streamline pre-processing while direct data management integration helps to ensure consistency across teams.

Integrated multiphysics simulation
Unified solvers and domain coupling allow engineers to analyze complex interactions – such as thermal-fluid or electromagnetic-structural systems – with greater fidelity. New workflows support e-motor optimization, battery safety studies, and high-temperature analysis, while co-simulation standards enhance digital continuity. Electromagnetic simulations run up to 40 percent faster and propagation modeling up to 20x faster with radar and electromagnetic compatibility (EMC) analysis expanded for next-generation applications.

Automation, collaboration and connectivity
Expanded Python and API support, intuitive no-code workflow tools, and cloud integration promote digital continuity. Enhanced visualization and plotting tools simplify result interpretation and sharing, while seamless interoperability with third-party software strengthens digital twin fidelity.

Realistic particle, fluid, and material behavior
New modeling approaches capture bulk flow, impact behavior, and high-temperature effects with greater realism. Python-based automation accelerates discrete element method (DEM) workflows and coupled solvers enable advanced studies of battery safety and material response.

Intuitive design and motion exploration
A more unified workspace transforms how engineers explore motion and refine geometry. Real-time updates across multi-window views reduce setup time, while flexible implicit modeling and direct surface editing remove geometry barriers to creativity. With clear side-by-side comparisons, teams can make faster, more confident decisions.

Altair HyperWorks 2026 is available now. To learn more, visit https://altair.com/hyperworks-2026

Media contacts

Altair Corporate
Bridget Hagan
+1.216.769.2658
corp-newsroom@altair.com                    

Altair Europe/The Middle East/Africa
Louise Wilce
+44 (0)7392 437 635
emea-newsroom@altair.com

Altair Asia-Pacific
Man Wang
86-21-5016635,,825
apac-newsroom@altair.com

About Altair
Altair is a global leader in computational intelligence that provides software and cloud solutions in simulation, high-performance computing (HPC), data analytics, and AI. Altair is part of Siemens Digital Industries Software. To learn more, please visit altair.com or sw.siemens.com.

XISHUANGBANNA, China, Dec. 8, 2025 /PRNewswire/ — As global competition for talent intensifies, organisations are increasingly elevating employer branding from a recruitment-focused activity to a core strategic capability. Authentic storytelling, employee-experience design and trust-building have become defining components of modern organisational competitiveness.

The 2025 Employer Branding Creativity Awards concluded successfully in Xishuangbanna on December 1. Hosted by the Employer Branding Institute, and supported by BusinessWeek/Chinese Edition, Xiaoguo and Lockin China, the Awards received 1,831 submissions from 534 organisations across the technology, finance, consumer goods, manufacturing, healthcare and service sectors. Participating organisations included Mercedes-Benz, AstraZeneca China, Bosch China, L’Oréal China, Marriott International and H&M, among others.

The international jury panel comprised leading employer-branding experts including Richard Mosley, Ali Ayaz and Barbara Zych, alongside cross-disciplinary leaders from marketing, public welfare and business media. Using the Institute’s “4+1” evaluation framework — Content Operation, Creative Design, Communication Strategy, User Experience plus an additional targeted criterion — the panel selected 160 outstanding entries representing 74 organisations.

Ms Ocean Fu, Founder of the Employer Branding Institute, said: “Over the past nine years, we have seen employer branding shift from storytelling to trust-building. In a workplace reshaped by AI, efficiency accelerates, yet understanding between people and organisations takes more time. Algorithms may optimise processes, but they cannot build trust. True employer branding helps employees understand and navigate change, rather than simply polishing it.” She continued: “As AI restructures workflows, the value of employer branding lies in helping each employee find their place. Real brand vitality does not come from packaging, but from understanding people. We hope more organisations will move beyond efficiency-driven practices to cultivate ecosystems of trust — where employees of diverse generations and backgrounds feel genuinely seen and supported.“

This year’s entries highlighted several notable shifts: a growing emphasis on employee-experience design; increasing adoption of AI-enabled communication; organisational culture becoming central to employer-brand storytelling; and rising cross-department collaboration in content creation.

The newly introduced Achievement Award recognised excellence in organisational talent strategy. Honourees included teams from Lianjia, BEIJING FANUC, Bosch China, Greentown China Holdings Limited, Marriott International and Mercedes-Benz.

The organisers announced plans to expand international participation and strengthen global exchange mechanisms for the 2026 edition. Registration for the 2026 Awards will open in May 2026.

About Employer Branding Institute

The Employer Branding Institute (EBI) is a leading research institution dedicated to employer-brand strategy, research and innovation. EBI brings together global authorities including Simon Barrow, originator of the employer-brand concept, and Richard Mosley, widely regarded as the “Father of Employer Branding”. The Institute serves more than 2,000 clients worldwide, including over 300 Fortune Global 500 companies.

EBI is co-branded by HRflag and Wild Theory, reinforcing its leadership in advancing employer branding and belonging practices globally.

Early Phase 1 monotherapy data demonstrate cytopenia-sparing safety, broad pharmacologic window, and early clinical activity in relapsed/refractory non-Hodgkin lymphoma (NHL)

TAIPEI, SHANGHAI, and SAN FRANCISCO, Dec. 8, 2025 /PRNewswire/ — HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today presented new first-in-human data from its ongoing Phase 1 monotherapy study of HCB101, a 3.5^th-generation SIRPα-Fc fusion protein, in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) at the 67^th Annual Meeting of the American Society of Hematology (ASH), held December 6-9, 2025, in Orlando, Florida.

The ASH Annual Meeting is the world’s premier platform for clinical and translational advances in hematology. This year, over 8,200 abstracts were accepted globally, reaffirming ASH’s position as one of the most competitive and influential medical congresses in hematology and oncology, with historical rejection rates of approximately 28%.

The accepted abstract (#3299) features a focused sub-analysis from HanchorBio’s ongoing multinational, open-label Phase 1 study (NCT05892718) evaluating HCB101 monotherapy across solid and hematologic malignancies, highlighting results from the R/R NHL cohort.

Key Results (data cutoff: October 14, 2025):

• Thirteen patients with R/R NHL received HCB101 (5.12 – 24.0 mg/kg QW). No dose-limiting toxicities (DLTs) were observed, and the maximum tolerated dose (MTD) was not reached.
• All treatment-related adverse events were Grade 1-2, confirming a cytopenia-sparing safety profile.
• CD47 receptor occupancy (RO) reached ≥ 75-85% at 1.2 mg/kg and ≥ 90% at 8 mg/kg, demonstrating a broad pharmacologic window.
• A confirmed partial response (PR) was observed in a patient with marginal zone B-cell lymphoma at 8.00 mg/kg, with -43.3% tumor reduction at Week 8 deepening to -89.5% by Week 16 at the same dose.

The results were presented by Alvin Luk, PhD, MBA, CCRA, President & Chief Medical Officer and Chief Executive Officer (U.S.) of HanchorBio during the ASH 2025 poster session. Dr. Luk recently joined HanchorBio to lead the company’s global development of late-stage products and U.S. operations, advancing its next-generation immuno-oncology pipeline.

“Despite ASH’s highly competitive selection process, the inclusion of HCB101 monotherapy data reflects the strong translational foundation and clinical potential of our SIRPα-CD47 backbone,” said Scott Liu, Ph.D., Founder, Chairman, and Chief Executive Officer of HanchorBio. “We’re encouraged by the favorable safety and early signs of clinical activity seen in the heavily pretreated patient population. These findings validate the translational strength of our FBDB™ platform, and we look forward to engaging with the global hematology community as we expand HCB101 into hematologic malignancies and macrophage/T-cell combination strategies.”

“Presenting these data at ASH marks an important step for HanchorBio and our team,” added Dr. Alvin Luk. “Moving from molecular design to early clinical validation highlights the potential of selective SIRPα-CD47 blockade to achieve both safety and effective immune activation in patients with limited treatment options.”

About HCB101: A Differentiated CD47-SIRPα Blockade
HCB101 is a 3.5^th-generation, affinity-optimized SIRPα-Fc fusion protein with an intact IgG4 Fc backbone, developed using HanchorBio’s proprietary FBDB™ platform. It is engineered for selective CD47 targeting with low red blood cell (RBC) binding, thereby avoiding the anemia and thrombocytopenia commonly associated with earlier anti-CD47 monoclonal antibodies, while preserving strong antibody-dependent cellular phagocytosis (ADCP) and innate-to-adaptive immune bridging. Key differentiators of HCB101:

• Enhanced safety: Cytopenia-sparing profile, with no DLTs observed up to 30 mg/kg and receptor occupancy >90% at ≥1.28 mg/kg, supporting a broad therapeutic window.
• Robust immune activation: Engineered to enhance ADCP and bridge innate-to-adaptive immunity, with evidence of durable immune-mediated tumor control in monotherapy.
• Broad tumor applicability: Demonstrated activity across >80 PDX and CDX preclinical models, with early clinical signals in gastric cancer, TNBC, HNSCC, non-Hodgkin lymphoma, and ovarian cancer.
• Clinical translation: Shows durable disease control as monotherapy and a 100% confirmed partial response rate (6/6) in 2L gastric cancer when combined with ramucirumab and paclitaxel, with additional confirmed responses in 1L TNBC and 2L HNSCC, substantially exceeding historical benchmarks.

About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (TPEx: 7827) is a global biotechnology company specializing in immuno-oncology. It is led by an experienced team of pharmaceutical industry veterans with a proven track record in biologics discovery and international development, aiming to rewrite the landscape of cancer therapies. Committed to reactivating the immune system to fight diseases, the proprietary Fc-based designer biologics (FBDB™) platform enables the development of unique biologics with diverse multi-targeting modalities, unleashing both innate and adaptive immunity to overcome the current challenges of anti-PD1/L1 therapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By advancing breakthroughs in multi-functional, innovative molecular configurations in R&D and improving CMC manufacturing processes, HanchorBio develops transformative medicines to address unmet medical needs. For more information, please visit: https://www.HanchorBio.com